Shenzhen Chipscreen Biosciences Past Earnings Performance
Past criteria checks 2/6
Shenzhen Chipscreen Biosciences has been growing earnings at an average annual rate of 36.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 26.7% per year. Shenzhen Chipscreen Biosciences's return on equity is 3.9%, and it has net margins of 18.8%.
Key information
36.3%
Earnings growth rate
34.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 26.7% |
| Return on equity | 3.9% |
| Net Margin | 18.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%
Apr 24
Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)
Apr 05Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up
Mar 06Revenue & Expenses BreakdownBeta
How Shenzhen Chipscreen Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 548 | 103 | 369 | 270 |
| 31 Dec 23 | 524 | 89 | 369 | 270 |
| 30 Sep 23 | 543 | 168 | 361 | 246 |
| 30 Jun 23 | 556 | 192 | 364 | 250 |
| 31 Mar 23 | 532 | -11 | 331 | 180 |
| 31 Dec 22 | 530 | 17 | 317 | 164 |
| 30 Sep 22 | 490 | 4 | 307 | 167 |
| 30 Jun 22 | 463 | 10 | 299 | 148 |
| 31 Mar 22 | 460 | 26 | 293 | 141 |
| 31 Dec 21 | 430 | 22 | 289 | 130 |
| 30 Sep 21 | 360 | -32 | 271 | 126 |
| 30 Jun 21 | 342 | -5 | 236 | 115 |
| 31 Mar 21 | 312 | 19 | 202 | 107 |
| 31 Dec 20 | 269 | 31 | 164 | 92 |
| 30 Sep 20 | 231 | 37 | 149 | 69 |
| 30 Jun 20 | 202 | 31 | 131 | 65 |
| 31 Mar 20 | 181 | 23 | 115 | 54 |
| 31 Dec 19 | 174 | 19 | 107 | 51 |
| 30 Sep 19 | 181 | 37 | 89 | 52 |
| 30 Jun 19 | 157 | 31 | 84 | 45 |
| 31 Mar 19 | 142 | 28 | 79 | 42 |
| 31 Dec 18 | 148 | 31 | 80 | 43 |
| 31 Dec 17 | 111 | 24 | 54 | 38 |
| 31 Dec 16 | 85 | 5 | 48 | 32 |
Quality Earnings: 688321 has a high level of non-cash earnings.
Growing Profit Margin: 688321 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688321's earnings have grown significantly by 36.3% per year over the past 5 years.
Accelerating Growth: 688321 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 688321 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 688321's Return on Equity (3.9%) is considered low.